References

Inborn errors of immunity: an expanding universe of disease and genetic architecture

10.1038/s41576-023-00656-z · 2024 · External reference

2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases

10.1136/ard-2022-223335 · 2023 · External reference

Infectious disease screening prior to systemic immunomodulatory therapy in hidradenitis suppurativa: Consensus guidelines from the Asia-Pacific Hidradenitis Suppurativa foundation

10.1159/000534575 · 2024 · External reference

Biologic therapies in rheumatoid arthritis and the risk of opportunistic infections: a meta-analysis

10.1093/cid/ciu185 · 2014 · External reference

Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies, and future directions

10.1053/j.gastro.2017.02.009 · 2017 · External reference

Humoral immune response to vaccines in patients with rheumatoid arthritis treated with tocilizumab: results of a randomised controlled trial (VISARA)

10.1136/annrheumdis-2013-204427 · 2015 · External reference

Use of recombinant Zoster vaccine in immunocompromised adults aged ≥19 years: recommendations of the Advisory Committee on immunization practices - united States, 2022

10.15585/mmwr.mm7103a2 · 2022 · External reference

Vaccinations in selected immune-related diseases treated with biological drugs and JAK inhibitors-literature review and statement of experts from Polish dermatological Society

10.3390/vaccines12010082 · 2024 · External reference

A systematic review and expert Delphi Consensus recommendation on the use of vaccines in patients receiving dupilumab: a position paper of the American College of Allergy, Asthma and immunology

10.1016/j.anai.2024.05.014 · 2024 · External reference

Vaccinations in patients with immune-mediated inflammatory diseases

10.1093/rheumatology/keq183 · 2010 · External reference

Side effects following vaccination in multiple sclerosis: a prospective, multi-centre cohort study

10.1038/s41598-023-41271-6 · 2023 · External reference

B cell depletion impairs vaccination-induced CD8+ T cell responses in a type I interferon-dependent manner

10.1136/annrheumdis-2021-220435 · 2021 · External reference

B-cell targeted therapeutics in clinical development

2013 · External reference

Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study

10.1186/1471-2334-13-317 · 2013 · External reference

Hepatitis B reactivation and rituximab in the oncology practice

10.1634/theoncologist.2010-0106 · 2010 · External reference

Late reactivation of hepatitis B virus after chemotherapies for hematological malignancies: a case report and review of the literature

10.2169/internalmedicine.56.7468 · 2017 · External reference

Rituximab-related viral infections in lymphoma patients

10.1080/10428190701411441 · 2007 · External reference

Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance

10.1002/hep.29800 · 2018 · External reference

Safety and immunogenicity of inactivated varicella-zoster virus vaccine in adults with hematologic malignancies receiving treatment with anti-CD20 monoclonal antibodies

10.1016/j.vaccine.2016.10.055 · 2017 · External reference

B-cell therapies in established rheumatoid arthritis

10.1016/j.berh.2011.10.005 · 2011 · External reference

Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis

10.1136/ard.2010.144998 · 2011 · External reference

Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry

10.1002/art.27555 · 2010 · External reference

Safety experience with continued exposure to ofatumumab in patients with relapsing forms of multiple sclerosis for up to 3.5 years

10.1177/13524585221079731 · 2022 · External reference

Tolerability and safety of rituximab (MabThera)

10.1016/j.ctrv.2005.05.007 · 2005 · External reference

Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study

10.1002/art.27189 · 2010 · External reference

Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus

10.1002/art.34564 · 2012 · External reference

BTK inhibitors: past, present, and future

10.1016/j.tips.2024.06.006 · 2024 · External reference

Chronic lymphocytic leukemia and infection risk in the era of targeted therapies: linking mechanisms with infections

10.1016/j.blre.2018.03.004 · 2018 · External reference

Incidence of opportunistic infections during ibrutinib treatment for B-cell malignancies

10.1038/s41375-019-0481-1 · 2019 · External reference

No clinically meaningful impact of remibrutinib on mean immunoglobulin levels or infections in chronic spontaneous urticaria

2025 · External reference

Infections in patients with chronic lymphocytic leukaemia: mitigating risk in the era of targeted therapies

10.1016/j.blre.2018.04.007 · 2018 · External reference

Incidence and management of toxicity associated with ibrutinib and idelalisib: a practical approach

10.3324/haematol.2017.164103 · 2017 · External reference

A randomized, placebo-controlled phase 3 trial of the PI3Kδ inhibitor leniolisib for activated PI3Kδ syndrome

10.1182/blood.2022018546 · 2023 · External reference

Idelalisib impairs T-cell-mediated immunity in chronic lymphocytic leukemia

10.3324/haematol.2017.187070 · 2018 · External reference

Infectious complications of biological and small molecule targeted immunomodulatory therapies

10.1128/cmr.00035-19 · 2020 · External reference

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

10.1182/blood-2013-11-535047 · 2014 · External reference

Phosphatidylinositol 3-Kinase inhibition by Copanlisib in relapsed or refractory indolent lymphoma

10.1200/jco.2017.75.4648 · 2017 · External reference

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: a multidisciplinary position paper

10.1002/hon.2540 · 2019 · External reference

Risk of hospitalized infection and initiation of Abatacept versus tumor necrosis factor inhibitors among patients with rheumatoid arthritis: a propensity score-matched cohort study

10.1002/acr.23824 · 2020 · External reference

Post-marketing safety of anakinra and canakinumab: a real-world pharmacovigilance study based on FDA adverse event reporting system

2025 · External reference

Rilonacept (Interleukin-1 inhibition) for the treatment of pericarditis

10.1007/s11886-021-01621-0 · 2022 · External reference

Long-term safety profile of anakinra in patients with severe cryopyrin-associated periodic syndromes

10.1093/rheumatology/kew208 · 2016 · External reference

Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet’s disease

10.1016/j.autrev.2014.08.008 · 2015 · External reference

Dupilumab: mechanism of action, clinical, and translational science

10.1111/cts.13899 · 2024 · External reference

No increased risk of overall infection in adults with moderate-to-severe atopic dermatitis treated for up to 4 years with dupilumab

10.1007/s12325-022-02322-y · 2023 · External reference

Adverse events of dupilumab in adults with moderate-to-severe atopic dermatitis: a meta-analysis

10.1016/j.intimp.2017.11.031 · 2018 · External reference

Unresolved reference

External reference

Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study

10.1016/j.jaad.2020.09.084 · 2021 · External reference

A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database

10.3389/fphar.2023.1320458 · 2023 · External reference

Safety of ixekizumab in patients with psoriatic arthritis: data from four clinical trials with over 2000 patient years of exposure

10.1136/annrheumdis-2021-222027 · 2022 · External reference

Secukinumab - first in class Interleukin-17A inhibitor for the treatment of psoriasis

10.4103/ijd.ijd_233_16 · 2017 · External reference

Bimekizumab safety in patients with moderate to severe plaque psoriasis: pooled results from phase 2 and phase 3 randomized clinical trials

10.1001/jamadermatol.2022.1185 · 2022 · External reference

Brodalumab

2025 · External reference

Safety of Ixekizumab in patients with psoriatic arthritis: results from a pooled analysis of three clinical trials

10.1002/acr.23738 · 2019 · External reference

Infections from seven clinical trials of ixekizumab, an anti interleukin 17A monoclonal antibody, in patients with moderate to severe psoriasis

10.1111/bjd.15723 · 2017 · External reference

The safety of ustekinumab treatment in patients with moderate-to-severe psoriasis and latent tuberculosis infection

10.1111/j.1365-2133.2012.11142.x · 2012 · External reference

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

10.1146/annurev.immunol.19.1.163 · 2001 · External reference

Infectious complications associated with immunomodulating biologic agents

10.1016/j.idc.2010.01.006 · 2010 · External reference

Binding and functional comparisons of two types of tumor necrosis factor antagonists

10.1124/jpet.301.2.418 · 2002 · External reference

Difference in the risk of serious infections in patients with rheumatoid arthritis treated with adalimumab, infliximab and etanercept: results from the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

10.1136/annrheumdis-2012-201338 · 2013 · External reference

Filgotinib: a clinical pharmacology review

10.1007/s40262-022-01129-y · 2022 · External reference

Herpes zoster and tofacitinib therapy in patients with rheumatoid arthritis

10.1002/art.38745 · 2014 · External reference

Real-world comparative effectiveness and safety of tofacitinib and baricitinib in patients with rheumatoid arthritis

10.1186/s13075-021-02582-z · 2021 · External reference

Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies

10.1016/s1474-4422(17)30282-x · 2017 · External reference

Mycophenolate mofetil

10.1016/s0140-6736(96)10310-x · 1996 · External reference

Antimetabolites in the treatment of arthritis: current status of the use of antimetabolites

10.1081/ncn-200027360 · 2004 · External reference

Therapy of rheumatoid arthritis with mycophenolate mofetil

1993 · External reference

Effect of mycophenolate mofetil on the white blood cell count and the frequency of infection in systemic lupus erythematosus

10.1007/s00296-015-3265-6 · 2015 · External reference

Ocular complications of heart, lung and liver transplantation

10.1136/bjo.82.4.423 · 1998 · External reference

Mycophenolate mofetil increases cytomegalovirus invasive organ disease in renal transplant patients

10.1034/j.1399-0012.2000.140206.x · 2000 · External reference

Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses

10.1111/j.1399-0012.1998.tb01091.x · 1998 · External reference

Cytomegalovirus infection after liver transplantation: current concepts and challenges

10.3748/wjg.14.4849 · 2008 · External reference

Risk of infection with methotrexate therapy in inflammatory diseases: a systematic review and meta-analysis

10.3390/jcm8010015 · 2018 · External reference

Infection in organ transplantation

10.1111/ajt.14208 · 2017 · External reference

Methods to avoid infections in patients with inflammatory bowel disease

10.1097/01.mib.0000160742.91602.b7 · 2005 · External reference

Incidence of Pneumocystis jirovecii Pneumonia and prophylaxis-associated adverse events among patients with systemic lupus erythematosus

2025 · External reference